Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVE-Lp(a): Muvalaplin for Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a)
jRCT2031250354Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in lipoprotein(a) hyperlipoproteinemia (Lp(a)), atherosclerotic disease, coronary arteriosclerosis and 2 more comparing Muvalaplin with Placebo (2 arms). Primary endpoint: Time to first occurrence of any component of the MACE-4 composite endpoint. Started Oct 2025; status: recruiting.
02
Drugs
muvalaplin
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))atherosclerotic diseasecoronary arteriosclerosiscerebrovascular diseasearteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2031250354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250354.